40 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
2 May 24
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
7:09am
between our mission of bringing new, innovative medicines to patients and building a robust and thriving business that will create substantial value
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
25 Apr 24
Other Events
8:30am
and degranulation of mast cells is an innovative approach to how we treat several allergic disorders. Blueprint is well positioned to succeed in large
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
are investing in our most compelling opportunities to deliver innovative, life-changing medicines to patients, while maintaining a strong and sustainable
8-K
EX-99.1
yoh3ae4u yx
22 May 23
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
4:53pm
8-K
EX-99.1
sy5 gqxrt8dc2
2 Aug 22
Blueprint Medicines Reports Second Quarter 2022 Results
7:47am
8-K
EX-99.1
byz tbap9tvnc1v3
3 May 22
Blueprint Medicines Reports First Quarter 2022 Results
7:45am
8-K
EX-99.2
p88ymdc18nadmjp
8 Apr 22
Regulation FD Disclosure
1:20pm
424B5
iidi cadzk35n
17 Feb 22
Prospectus supplement for primary offering
8:59am
8-K
EX-99.1
uqzi1
10 Jan 22
Regulation FD Disclosure
8:27am
8-K
EX-99.2
woff68pd1f5nr u6o
10 Jan 22
Regulation FD Disclosure
8:27am
8-K
EX-99.1
7y3zzva
5 Jan 22
Blueprint Medicines Announces CEO and Leadership Transition Plan
8:07am
8-K
EX-99.1
f7z 8moq35kctz3f
9 Nov 21
Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
8:39am
8-K
EX-10.1
2aov4e nd1k6
28 Jul 21
Other Events
4:15pm
8-K
EX-99.1
pior25b
17 May 21
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
8:30am